Infliximab biosimilar SB2 shows efficacy, safety similar to Remicade for RA

The investigational infliximab biosimilar drug SB2 provided efficacy and safety equivalent to the originator drug Remicade in patients with moderate to severe rheumatoid arthritis in a phase III...